Market Cap 3.56B
Revenue (ttm) 781.37M
Net Income (ttm) -197.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -25.32%
Debt to Equity Ratio 2.31
Volume 1,265,500
Avg Vol 2,229,690
Day's Range N/A - N/A
Shares Out 126.29M
Stochastic %K 84%
Beta 0.69
Analysts Strong Sell
Price Target $38.05

Company Profile

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproli...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 977 5700
Website: apellis.com
Address:
100 Fifth Avenue, Waltham, United States
buylowandwait
buylowandwait Oct. 24 at 4:43 PM
$APLS The company was valued at 90+ dollar based on GA promise. However, in the last few quarters, the GA revenue stopped growing, which triggered big sell-off along with drama from extremely rare blindness triggered by injection. If Q3, GA resumes growth, or if there is guidance of resuming growth from the management team, this will take off. Keep in mind we have C3G/IC-MPGN launch ongoing, which is an very effective drug. 100K+ shares holding !
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 24 at 1:23 PM
$APLS next week -will it be a trick or a treat...
0 · Reply
philosophernutz
philosophernutz Oct. 23 at 2:44 PM
$APLS a little bit of momentum....
0 · Reply
RonIsWrong
RonIsWrong Oct. 23 at 2:05 PM
$APLS 👀 I picked up some calls 3 days ago 🤷‍♂️
3 · Reply
buylowandwait
buylowandwait Oct. 22 at 7:51 PM
$APLS 30+ Soon. Fundamentals are strong ! Scientists are running the company, not ideal, but the company assets are real. The drugs works and worths a lot more than the current valuation.
0 · Reply
philosophernutz
philosophernutz Oct. 21 at 10:23 PM
$APLS I think the analysts already know the numbers are gonna come out better than expected, that's why we're seeing these random upgrades.
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 21 at 7:58 PM
$APLS buying it up at the closing...come out you thieves.
0 · Reply
Jay4profit
Jay4profit Oct. 21 at 4:05 PM
$APLS looks good!
0 · Reply
The_Fact_ster
The_Fact_ster Oct. 21 at 3:55 PM
$APLS Feb 5th... the last time the stock price here was above $30/shr What a bizarre fricken year.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 21 at 3:34 PM
$APLS Hopefully they can run this up to $30 before the call and if we get lucky with sales numbers we could get some upgrades and move to $35. I know I'm dreamin...
1 · Reply
Latest News on APLS
Apellis Pharmaceuticals: The Picture Becomes Clearer

Aug 1, 2025, 2:29 PM EDT - 3 months ago

Apellis Pharmaceuticals: The Picture Becomes Clearer


Apellis Pharmaceuticals: Have Some Patience

May 20, 2025, 9:28 AM EDT - 5 months ago

Apellis Pharmaceuticals: Have Some Patience


Apellis Announces Craig Wheeler to Join the Board of Directors

Apr 21, 2025, 7:00 AM EDT - 6 months ago

Apellis Announces Craig Wheeler to Join the Board of Directors


FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

Apr 1, 2025, 2:11 PM EDT - 7 months ago

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals


Apellis Pharmaceuticals: A Mixed Bag

Mar 5, 2025, 2:06 PM EST - 8 months ago

Apellis Pharmaceuticals: A Mixed Bag


buylowandwait
buylowandwait Oct. 24 at 4:43 PM
$APLS The company was valued at 90+ dollar based on GA promise. However, in the last few quarters, the GA revenue stopped growing, which triggered big sell-off along with drama from extremely rare blindness triggered by injection. If Q3, GA resumes growth, or if there is guidance of resuming growth from the management team, this will take off. Keep in mind we have C3G/IC-MPGN launch ongoing, which is an very effective drug. 100K+ shares holding !
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 24 at 1:23 PM
$APLS next week -will it be a trick or a treat...
0 · Reply
philosophernutz
philosophernutz Oct. 23 at 2:44 PM
$APLS a little bit of momentum....
0 · Reply
RonIsWrong
RonIsWrong Oct. 23 at 2:05 PM
$APLS 👀 I picked up some calls 3 days ago 🤷‍♂️
3 · Reply
buylowandwait
buylowandwait Oct. 22 at 7:51 PM
$APLS 30+ Soon. Fundamentals are strong ! Scientists are running the company, not ideal, but the company assets are real. The drugs works and worths a lot more than the current valuation.
0 · Reply
philosophernutz
philosophernutz Oct. 21 at 10:23 PM
$APLS I think the analysts already know the numbers are gonna come out better than expected, that's why we're seeing these random upgrades.
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 21 at 7:58 PM
$APLS buying it up at the closing...come out you thieves.
0 · Reply
Jay4profit
Jay4profit Oct. 21 at 4:05 PM
$APLS looks good!
0 · Reply
The_Fact_ster
The_Fact_ster Oct. 21 at 3:55 PM
$APLS Feb 5th... the last time the stock price here was above $30/shr What a bizarre fricken year.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 21 at 3:34 PM
$APLS Hopefully they can run this up to $30 before the call and if we get lucky with sales numbers we could get some upgrades and move to $35. I know I'm dreamin...
1 · Reply
philosophernutz
philosophernutz Oct. 21 at 12:27 PM
$APLS Mofo analysts are expecting positive earnings. $1.06 a share. Let's hope APLS doesn't drop the ball again. 😭
0 · Reply
Jennifur
Jennifur Oct. 21 at 12:21 PM
$APLS I had a talk with Cedric and put him in his place.....
0 · Reply
monoksop
monoksop Oct. 20 at 7:43 PM
$APLS Piper Sandler raised their price target from $28 to $30. It ain’t much, but it’s honest work.
0 · Reply
buylowandwait
buylowandwait Oct. 20 at 6:02 PM
$APLS Keep in mind that the two assets are blockbuster each. With GA being a multi-billion opportunity, and C3G/IC-MPGN will hit blockbuster in a few short years. Yet, the enterprise value is less than 3B. I see minimum 5B enterprise value with the current XBI environment, which translates into 50 PPS.
1 · Reply
buylowandwait
buylowandwait Oct. 20 at 5:58 PM
$APLS How high can this go? 30+ near term. I am actually surprised that this isn't 30 already given the strong recovery from XBI. Long with 100K+ shares, barely break even and waiting for further price appreciation. Jennifer, keep on bitching, you go girl....
1 · Reply
monoksop
monoksop Oct. 20 at 4:25 PM
$APLS Almost like this is exactly what happened. Better start calling me the APLS whisperer.
2 · Reply
ThatsNoMoon
ThatsNoMoon Oct. 20 at 3:53 PM
$APLS LFG!
0 · Reply
4Reel
4Reel Oct. 20 at 1:11 PM
$APLS yep great news again. Already got BOA to raise a price target too. 30 by end of the yr, sooner than later imo
0 · Reply
Jennifur
Jennifur Oct. 16 at 9:59 PM
$APLS Will probably find out at earnings that management blew the whole 300 million Sobi royalty cash on R&D
2 · Reply
Still_a_Chance
Still_a_Chance Oct. 16 at 2:35 PM
$APLS break $26 and 🚀
1 · Reply
Winning_calls
Winning_calls Oct. 16 at 2:18 PM
$APLS join our team
1 · Reply
philosophernutz
philosophernutz Oct. 16 at 2:09 PM
$APLS Here we go, it's go time. Can we get positive earnings? https://finance.yahoo.com/news/apellis-pharmaceuticals-host-conference-call-110000268.html
1 · Reply